# MHC ANTIGEN EXPRESSION IN TERATOCARCINOMA CELLS

> **NIH NIH R01** · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · 1988 · $149,366

## Abstract

Many studies have demonstrated that some individuals display an efficient
immune response against resident tumor cells.  In many cases such a
response can be shown to effectively reject a tumor.  Studies from this
laboratory have demonstrated that the ability to reject a particular tumor
(402AX teratocarcinoma) is under genetic control in mice, and that
rejection is accomplished by the resistant individual's immune system.  The
goal of the studies proposed in this application is to define the
differences between mice susceptible to the 402AX tumor.  Initial studies
have indicated that resistant mice have the capability to induce the
expression of particular molecules on the tumor cells (major
histocompatibility complex (MHC) antigens) and that these molecules are
subsequently used by the host's immune system to recognize and reject the
resident tumor cells.  The resistant mouse, therefore, can manipulate its
tumor cells such that they display molecules that are used to reject the
tumor, while the susceptible mouse has no capability to modulate tumor cell
molecule expression.  The present experiments are aimed at understanding
the mechanism(s) by which the resistant mouse induces expression of these
MHC antigens.  An understanding of this phenomenon would further define why
certain individuals are susceptible to tumors while other individuals are
resistant to tumors.  In addition, once the mechanism of regulation is
understood, one would have the information with which to convert
susceptible individuals to resistant individuals.

## Key facts

- **NIH application ID:** 3172065
- **Project number:** 5R01CA034368-06
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE COUNTY
- **SAM.gov UEI:** RNKYWXURFRL5
- **Principal Investigator:** SUZANNE OSTRAND-ROSENBERG
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $149,366
- **Award type:** 5
- **Project period:** 1983-05-01 → 1989-12-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172065

## Citation

> US National Institutes of Health, RePORTER application 3172065, MHC ANTIGEN EXPRESSION IN TERATOCARCINOMA CELLS (5R01CA034368-06). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172065. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*